DRKS00014689已完成2 期
A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors - RamuNET
Martin-Luther-Universität Halle-WittenbergMedizinische Fakultät0 个研究点目标入组 45 人开始时间: 2018年10月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Histologically confirmed unresectable metastatic G1-G3 differentiated pancreatic neuroendocrine tumor (non-functional and functional NET) with a proliferation rate assessed by Ki-67 up to 55% excluding neuroendocrine carcinomas
- •- Age: 18-80 years
- •- Measurable disease (RECIST 1.1)
- •- Progressive disease under treatment with either non-DTIC-based chemotherapy, SSA analogues, everolimus or sunitinib. No prior therapy with DTIC C is allowed. Prior therapy with temozolomide is allowed with a temozolomide-free interval of at least 6 months prior to trial inclusion. Prior TACE and SIRT allowed with a minimum of 3 months before study entry, prior PRRT with a minimum of 12 months before study entry
- •- ECOG 0-1
- •- Life expectancy > 12 weeks
- •- Adequate renal, hepatic, bone marrow and coagulation function
- •- Sexually active patiens: postmenopausal, surgically sterile, or use of effective contraception (Pearl Index <1). Female patients of childbearing potential: negative serum pregnancy test within 7 days prior to first dose
- •of protocol therapy.
- •- Written informed consent
排除标准
- •- Secondary malignancy in patient's history with the exception of: disease-free period > 5 years before randomization or non-melanoma skin cancer or curatively treated cervical carcinoma in situ or other
- •noninvasive in situ neoplasm.
- •- Allergy against dacarbazine or ramucirumab
- •- Current enrolment or participation within the last 4 weeks in a clinical drug trial
- •- Any arterial thromboembolic events within 6 months prior to first dose of protocol therapy.
- •- Insufficient liver function
- •- Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management
- •- Chronic antiplatelet therapy, once-daily aspirin use (maximum dose 325 mg/day) permitted
- •- Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy.
- •- History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered significant) during the 3 months prior to first dose of protocol therapy
- •- Uncontrolled severe physical or mental disorders
- •- Pathological condition present that carries a high risk of bleeding
- •- History of gastrointestinal perforation/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation.
- •- Major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy. Elective or planned major surgery to be performed during the course of the clinical trial.
- •- Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic neuroendocrine tumors of the pancreasProgressive well-differentiated metastatic pancreatic neuroendocrine tumorsMedDRA version: 21.0Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 100000004864EUCTR2017-001207-68-DEMartin-Luther-Universität Halle-Wittenberg45
招募中
不适用
A multicenter, single-arm, phase II study of ramucirumab plus FOLFIRI with 150 mg/m2 irinotecan, standard Nippon dose, as the second-line treatment for Japanese patients with metastatic colorectal cancercolorectal cancerJPRN-UMIN000025659agoya University Graduate School of Medicine60
进行中（未招募）
2 期
Study rindoJPRN-jRCTs041180074akayama Goro60
已完成
不适用
Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G)Gastric or colorectal neuroendocrine carcinoma (NEC)JPRN-UMIN000043200West Japan Oncology Group160
进行中（未招募）
1 期
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6